Business context and reporting period
This is Access Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2012. The request identifies Abeona Therapeutics, Inc., but the filing names Access Pharmaceuticals, Inc.; verify the issuer and filing before relying on this summary. Access described itself as an emerging biopharmaceutical company focused on drug-delivery technologies. Its marketed product was MuGard; ProLindac and Thiarabine were in clinical development, with other programs preclinical.
Financial performance and position
| Metric | Q1 2012 | Q1 2011 or prior-period comparison |
|---|---|---|
| Total revenue | $1.855 million | $150,000 |
| Operating expenses | $2.544 million | $2.299 million |
| Loss from operations | $689,000 | $2.149 million |
| Net loss allocable to common stockholders | $5.332 million; $0.22 per share | $2.337 million; $0.12 per share |
| Cash used in operating activities | $1.082 million | $837,000 |
| Cash and cash equivalents | $1.365 million | $2.460 million at December 31, 2011 |
| Working capital deficit | $10.136 million | $8.877 million at December 31, 2011 |
| Secured debt | $2.75 million, due September 13, 2012 | $2.75 million at December 31, 2011 |
MuGard U.S. product sales were $572,000 and related product costs were $537,000, a difference of $35,000 before other expenses. Licensing revenue was $1.262 million, including recognition of $706,000 of previously deferred European license fees and a $500,000 termination fee. The filing reports no cash paid for interest during the quarter. Total liabilities were $23.359 million and stockholders’ deficit was $20.163 million at March 31, 2012.
Material changes versus the prior comparable period
- Revenue rose to $1.855 million from $150,000, driven by the European license termination recognition and higher MuGard U.S. sales ($572,000 versus $13,000).
- Operating loss narrowed to $689,000 from $2.149 million, despite operating expenses increasing $245,000. Research and development expense declined $146,000 to $974,000.
- Common-stockholder loss increased to $5.332 million from $2.337 million. Q1 2012 included a $2.316 million warrant-extension expense and a $2.460 million loss from the preferred-stock derivative remeasurement; these were partly offset by a $741,000 gain on warrant derivative remeasurement.
- Operating cash use increased to $1.082 million from $837,000. Cash fell by $1.095 million during Q1, and the working capital deficit widened by $1.259 million from year-end.
Outlook, risks, contingencies and unusual items
- Management expected available capital, MuGard revenue and anticipated license receipts to fund the current operating level only into the third quarter of 2012. The company said it needed additional financing within 12 months and could not assure continued operations as a going concern without funding or new license agreements. Its auditor’s 2011 report had included a going-concern explanatory paragraph.
- The $2.75 million secured note was due September 13, 2012. The filing also reports $7.0 million of accrued preferred-stock dividends and $857,000 of accrued liquidated damages related to registration obligations.
- MuGard received Chinese marketing approval, and the company was seeking a new European commercial partner after mutually terminating its SpePharm agreement. SpePharm could continue European availability for up to six months. The filing describes ongoing clinical programs and collaborations but provides no financial guidance.
- Disclosure controls were deemed ineffective because a previously identified material weakness remained: financial reporting depended solely on the CFO, with inadequate segregation of duties and review. Management said it had not remediated the weakness.
- The company reported no legal proceedings believed to have a material impact on its financial condition or results.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Access Pharmaceuticals, Inc., not Abeona Therapeutics, Inc.
- Assess the near-term financing need, cash runway, and ability to repay or refinance the secured note due September 2012.
- Review the warrant-extension expense, derivative-liability valuations, and potential dilution from outstanding warrants and convertible preferred stock. The filing reported 24.15 million common shares outstanding at March 31, 2012 and preferred stock convertible into approximately 20.26 million common shares.
- Verify the sustainability and cash-conversion of MuGard sales, the European partner transition, and anticipated license receipts.
- Track accrued preferred dividends and registration-related liquidated damages, as well as remediation of the material weakness in financial reporting controls.